Advanced BioDesign is a French biotechnology company that is developing a new innovative targeted therapy against resistant cancers, with a first indication in acute myeloid leukemia (AML). Its main anticancer compound, DIMATE (ABD-3001), is a first-in-class suicide inhibitor of aldehyde dehydrogenases 1 & 3 (ALDH1 & 3). By inhibiting this enzyme, ABD-3001 causes cancer cell apoptosis without damaging healthy cells.

Contact

ismail.ceylan@a-biodesign.com

Address

655 ALLEE DES PARCS – BATIMENT D – 69800 SAINT-PRIEST

Website

www.a-biodesign.com

Targeted indications : Cancer du sein, Cancer du poumon, Cancer de la peau, Cancer hématologique

L’article Advanced BioDesign est apparu en premier sur OncoSTART.

The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system. Alderaan Biotechnology main program is related to the elimination of Regulatory T cells in the tumour microenvironment via targeting CD25.

Contact

contact@alderaan.fr

Address

04 rue Thénard, 75004 Paris

Website

alderaan-biotechnology.com

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Alderaan Biotechnology est apparu en premier sur OncoSTART.

Antineo is specialized in preclinical services to test future anticancer agents. We realize proof-of-concept studies in vitro, ex vitro and in vivo (CDX on immunocompromised, humanized mice, or syngeneic). Our expertise allows to optimize the preclinical steps of drug development strategies with the choice of the indication, relevant model, and adequate references/combinations. We also provide a panel of secondary resistance models (chemo and immunotherapies, immune checkpoint inhibitors).

Contact

contact@antineo.fr

Address

8 avenue Rockefeller 69008 Lyon

Website

www.antineo.fr

Targeted indications : breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, supportive care, liver cancer, brain cancer, head & neck cancer, gastrointestinal cancer, gynecological cancer, bone cancer, genitourinary cancer, skin cancer, hematologic cancer, lymphoma, myeloma, leukemia, predictive toxicology.

L’article Antineo SAS est apparu en premier sur OncoSTART.

Apmonia Therapeutics is a biotech company committed to develop therapeutic strategies towards multiple types of cancer.

We are developing a first-in-class pipeline of next-generation peptide-based therapies targeting the tumor microenvironment to improve the lives of patients with cancer.

Contact

contact@apmonia-therapeutics.com

Address

CREA, 2 Esplanade Roland Garros, 51100 REIMS

Website

Apmonia Therapeutics

Targeted indications : Colorectal cancer, Brain cancer, Gastrointestinal cancers, Gynecological cancers

L’article Apmonia Therapeutics est apparu en premier sur OncoSTART.

Brenus Pharma is a innovative French biotech developing allogeneic cell-based vaccines for immunotherapy of solid cancers in order to fight treatments resistances.

Contact

pbravetti@brenus-pharma.com

Address

La Béchade Pit de Lavaur

Website

www.brenus-pharma.com

Targeted indications : Lung cancer, Colorectal cancer, Liver cancer, Gastrointestinal cancers, Skin cancer

L’article Brenus Pharma est apparu en premier sur OncoSTART.

Carthera is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat brain tumors and other severe brain disorders.
Carthera has developed SonoCloud, a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.

Contact

contact@carthera.eu

Address

Institut du Cerveau, Hôpital Pitié Salpêtrière, 47-83 bd de l’Hôpital, 75013 PARIS (FRANCE)

Website

www.carthera.eu

Targeted indications : brain cancer

L’article Carthera est apparu en premier sur OncoSTART.

Contact: contact@deeptope.com

Website: www.deeptope.com

L’article Deeptope est apparu en premier sur OncoSTART.

DIVINCELL is a French Biotech Company, pioneering a novel drug delivery technology for targeted cancer therapies. Our nanoparticle platform enables safe and efficient targeted delivery of therapeutic nucleic compounds. Our lead candidates combine the potency of our nanocarrier with CRISPR and mRNA strategies, to specifically silence KRAS oncogene mutations and rescue tumor suppressor functions.

Contact

divita.gilles@divincell-nanotechnology.fr

Address

Website

www.divincell-nanotechnology.fr

Targeting innovation :  All

L’article DIVINCELL est apparu en premier sur OncoSTART.

Domain Therapeutics is a preclinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for immuno-oncology. Based in France and Canada, Domain operates multiple technologies aimed at validating G Protein-Coupled Receptors (GPCRs) mediating immunosuppression, at discovering first-in-class or best-in-class therapies, small molecules and antibodies, and at developing them in the clinic to create a pipeline of high-value proprietary programs.

Contact

msidhoum@domaintherapeutics.com

Address

Website

www.domaintherapeutics.com

Targeting innovation :  All

L’article Domain Therapeutics est apparu en premier sur OncoSTART.

Contact :

CEO : Isabel Marey-Semper  contact@doxanano.com

Website : www.doxanano.com

Targeted indications : lung cancer, colorectal cancer, head & neck cancer, gastrointestinal cancer

L’article DOXANANO est apparu en premier sur OncoSTART.